Spero therapeutics to provide business update and report third quarter 2022 financial results on monday, november 14, 2022

Cambridge, mass., nov. 07, 2022 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that it will host a conference call and live audio webcast on monday, november 14, 2022 at 4:30 p.m. et to report its third quarter 2022 financial results and provide an update on its business and pipeline.
SPRO Ratings Summary
SPRO Quant Ranking